[
1. PLUMADORE E, LOMBARDO L, AND CABRAL KP. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. Am J health-Syst Pharm. 2022; 79:52–62.10.1093/ajhp/zxab35634491302
]Search in Google Scholar
[
2. PERFETTO F, ZAMPLERI M, FUMAGALLI C, ALLINOVI M, CAPPELLI F. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Internal and Emergency Medicine. 2022; 17:957–969.10.1007/s11739-022-02958-2913584535325395
]Search in Google Scholar
[
3. YAMAMOTO H, YOKOCHI T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019; 6:1128–1139.10.1002/ehf2.12518698927931553132
]Search in Google Scholar
[
4. GILLMORE JD, REILLEY MM, COATS CJ, COOPER R, COX H, COYNE MR, et al. Clinical and genetic evaluation of people with or without risk of hereditary ATTR amyloidosis: An expert opinion and consensus on best practice in Ireland and the UK. Adv Ther. 2022; 39:2292–2301.10.1007/s12325-022-02139-9912285735419651
]Search in Google Scholar
[
5. JAIN A, ZAHRA F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Treasure Island, 2022. PMID 34662045.
]Search in Google Scholar
[
6. ANDO Y, ADAMS D, BENSON MD, BERK JL, PLANTE-BORDENEUVE V, COELHO T, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;1–13.10.1080/13506129.2022.205283835652823
]Search in Google Scholar
[
7. OBI CA, MOSTERTZ WC, GRIFFIN JM, JUDGE DP. ATTR epidemiology, genetics, and prognostic factors. Methodist DeBakey Cardiovasc J. 2022;18(2):17–26.10.14797/mdcvj.1066893238535414855
]Search in Google Scholar
[
8. RIMBAS RC, BALINISTEANU A, MAGDA SL, VISOIU SI, CIOBANU AO, BEGANU E, et al. New advanced imaging parameters and biomarkers – a step forward in the diagnosis and prognosis of TTR cardiomyopathy. J Clin Med. 2022;11(2360):1–26.10.3390/jcm11092360910161735566485
]Search in Google Scholar
[
9. GROGAN M, SCOTT CG, KYLE RA, ZELDENRUST ST, GERTZ MA, LIN G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20.10.1016/j.jacc.2016.06.03327585505
]Search in Google Scholar
[
10. DONNELLAN E, WAZNI OM, SALIBA WI, BARANOSWKI B, HANNA M, MARTYN M, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019;30(11):2427–2432.10.1111/jce.1418031515942
]Search in Google Scholar
[
11. GILLMORE JD, DAMY T, FONTANA M, HUTCHINSON M, LACHMANN HJ, MARTINEZ-NAHARRO A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806.10.1093/eurheartj/ehx58929048471
]Search in Google Scholar
[
12. OBICI L, BERK JL, GONZÁLEZ-DUARTE A, COELHO T, GILLMORE J, SCHMID HH, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153–162.10.1080/13506129.2020.173079032131641
]Search in Google Scholar
[
13. STERN LK, PATEL J. Cardiac amyloidosis treatment. Methodist DeBakey Cardiovasc J. 2022;18(2):59–72.10.14797/mdcvj.1050893235935414852
]Search in Google Scholar
[
14. TSCHOPE C, ELSANHOURY A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J Clin Med. 2022;11(2148):1–14.10.3390/jcm11082148903157635456241
]Search in Google Scholar
[
15. KAMDAR F, TAN CM, RODRIGUEZ ER, MOAZAMI N, HANNA M. Intramural coronary light-chain amyloidosis and left ventricular assist device implantation. The Journal of Heart and Lung Transplantation. 2020;39(10):1163–1164.10.1016/j.healun.2020.07.00532736937
]Search in Google Scholar
[
16. Vyndaqel, Package insert. Pfizer Labs: 2020.
]Search in Google Scholar
[
17. Vyndamax, Package insert. Pfizer Labs: 2020.
]Search in Google Scholar
[
18. COELHO T, MAIA LF, MARTINS DA SILVA A, WADDINGTON CRUZ M, PLANTE-BORDENEUVE A, LOZERON P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.10.1212/WNL.0b013e3182661eb1409887522843282
]Search in Google Scholar
[
19. MAURER MS, SCHWARTZ JH, GUNDAPANENI B, ELLIOTT PM, MERLINI G, WADDINGTON-CRUZ M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.10.1056/NEJMoa180568930145929
]Search in Google Scholar
[
20. BERK JL, DYCK PJ, OBICI L, ZELDENRUST SR, SEKIJIMA Y, YAMASHITA T, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2011; 18(sup1):196–192.10.3109/13506129.2011.57435407321838485
]Search in Google Scholar
[
21. ADAMS D, GONZALEX-DUART A, O’RIORDAN WD, YANG CC, UEDA M, KRISTEN AV, et al. Patisiran, an RNAi therapeutic, for hereditarytransthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.10.1056/NEJMoa171615329972753
]Search in Google Scholar
[
22. HABTEMARIAM BA, KARSTEN V, ATTARWALA H, GOEL V, MELCH M, CLAUSEN VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372–382.10.1002/cpt.197432599652
]Search in Google Scholar
[
23. BENSON MD, WADDINGTON-CRUZ M, BERK JL, POLYDEFKIS M, DYCK PJ, WANG AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22–31. doi: 10.1056/NEJMoa1716793.29972757
]Open DOISearch in Google Scholar
[
24. JUDGE DP, HEITNER SB, FALK RH, MAURER MS, SHAH SJ, WITTELES RM, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285–295.10.1016/j.jacc.2019.03.01230885685
]Search in Google Scholar
[
25. GAMEZ J, SALVADO M, REIG N, SUNE P, CASASNOVAS C, ROJAS-GARCIA R, et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study(.). Amyloid. 2019;26(2):74–84.10.1080/13506129.2019.159770231119947
]Search in Google Scholar
[
26. SUHR O, GROGAN M, MARTINS DA SILVA A. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. 2021 AAN annual meeting abstracts. Neurology. 2021;96(22): e2783–e2788.10.1212/WNL.0000000000012044
]Search in Google Scholar
